Doctor Admits Guilt in Matthew Perry Ketamine Death Case

· 1 min read

article picture

In a significant development in the ongoing investigation into Matthew Perry's death, Dr. Mark Chavez has pleaded guilty to conspiracy to distribute ketamine. The 54-year-old physician appeared in a Los Angeles federal court on Wednesday, admitting to his role in supplying the drug that ultimately led to the "Friends" star's untimely demise.

Perry, known for his iconic role as Chandler Bing, was found dead in his Los Angeles home on October 28, 2023. The Los Angeles County Medical Examiner later ruled the 54-year-old actor's death as accidental, citing "acute effects of ketamine" as the primary cause.

As part of his plea agreement, Chavez has agreed to surrender his medical license and faces up to 10 years in prison. His sentencing is scheduled for April 2, 2025. Chavez's attorney, Matthew Binninger, stated that his client has "accepted responsibility" and is cooperating with the government.

The case has revealed a complex network of individuals allegedly involved in supplying Perry with ketamine. Chavez is one of five people facing federal charges in connection with the actor's death. He admitted to selling ketamine to Dr. Salvador Plasencia, another licensed medical doctor, with the understanding that it would be sold to Perry, who was struggling with addiction.

Two other defendants, Eric Fleming and Kenneth Iwamasa (Perry's live-in assistant), have already pleaded guilty to their respective charges. Fleming admitted to distributing the ketamine that killed Perry, while Iwamasa confessed to administering the drug on the day of Perry's death.

The remaining defendants, Dr. Plasencia and Jasveen Sangha (allegedly known as "The Ketamine Queen"), have pleaded not guilty and are awaiting trial.

This case has shed light on the dangers of ketamine abuse and the illegal distribution of prescription drugs. As the legal proceedings continue, it serves as a somber reminder of the devastating impact of addiction, even among those in the public eye.